The company said, “Withdraws formal revenue guidance due to recent growth headwind from U.S. FDA’s late-Q3 2024 warning on potential for substantially reduced activity of pemivibart through the PEMGARDA Fact Sheet and other media based on contested, third-party, non-peer-reviewed, non-reproducible, virologic activity data from a non-pemivibart antibody.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd reports preliminary Q3 PEMGARDA product revenue $9.3M
- Invivyd announces 12-month exploratory data from CANOPY Phase 3 trial
- Invivyd announces FDA update on Pemgarda fact sheet for SARS-CoV-2 variants
- Invivyd provides virology data, analysis of SARS-CoV-2 structural biology
- Invivyd announces business readiness update, granted EUA for PEMGARDA